Compass Therapeutics (CMPX) Competitors

Compass Therapeutics (NASDAQ:CMPX) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, community ranking, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

Do analysts rate CMPX or AUPH?

Compass Therapeutics currently has a consensus target price of $13.13, suggesting a potential upside of 440.12%. Aurinia Pharmaceuticals has a consensus target price of $11.50, suggesting a potential upside of 42.15%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Compass Therapeutics is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Therapeutics	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	3.11
Aurinia Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do insiders and institutionals hold more shares of CMPX or AUPH?

68.4% of Compass Therapeutics shares are owned by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 29.8% of Compass Therapeutics shares are owned by insiders. Comparatively, 12.2% of Aurinia Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Does the MarketBeat Community prefer CMPX or AUPH?

Aurinia Pharmaceuticals received 529 more outperform votes than Compass Therapeutics when rated by MarketBeat users. However, 81.36% of users gave Compass Therapeutics an outperform vote while only 73.41% of users gave Aurinia Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Compass Therapeutics	Outperform Votes 48 81.36%	Underperform Votes 11 18.64%
Aurinia Pharmaceuticals	Outperform Votes 577 73.41%	Underperform Votes 209 26.59%

Does the media prefer CMPX or AUPH?

In the previous week, Aurinia Pharmaceuticals had 6 more articles in the media than Compass Therapeutics. MarketBeat recorded 7 mentions for Aurinia Pharmaceuticals and 1 mentions for Compass Therapeutics. Compass Therapeutics' average media sentiment score of 1.89 beat Aurinia Pharmaceuticals' score of 1.63 indicating that Compass Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Compass Therapeutics	Very Positive
Aurinia Pharmaceuticals	Very Positive

Is CMPX or AUPH more profitable?

Compass Therapeutics has a net margin of 0.00% compared to Aurinia Pharmaceuticals' net margin of -10.23%. Aurinia Pharmaceuticals' return on equity of -4.41% beat Compass Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Therapeutics	N/A	-32.37%	-30.67%
Aurinia Pharmaceuticals	-10.23%	-4.41%	-3.07%

Which has better earnings and valuation, CMPX or AUPH?

Compass Therapeutics has higher earnings, but lower revenue than Aurinia Pharmaceuticals. Compass Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Therapeutics	$850K	395.33	-$42.49M	-$0.41	-5.93
Aurinia Pharmaceuticals	$247.30M	4.42	-$78.02M	$0.28	28.89

Which has more risk & volatility, CMPX or AUPH?

Compass Therapeutics has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500.

Summary

Compass Therapeutics beats Aurinia Pharmaceuticals on 13 of the 19 factors compared between the two stocks.